Solaris Energy Infrastructure To Replace Catalyst Pharmaceuticals In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On July 15, 2026

Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals

Italian pharmaceutical company Angelini Pharma has completed its acquisition of Catalyst Pharmaceuticals for approximately $4.1 billion USD ($3.5 billion EUR). The deal strengthens Angelini Pharma's global presence in brain health and rare diseases while expanding into the U.S. market. Blackstone will invest €1 billion in preferred equity, and CDP Equity will acquire a 23.5% stake in Angelini Pharma for approximately €1 billion.

8-K filing — CATALYST PHARMACEUTICALS, INC. (CPRX)

Filed: 2026-07-16 AccNo: 0001193125-26-304984 Size: 312 KB Item 2.01: Completion of Acquisition or Disposition of Assets Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Item 3.03: Material Modifications to Rights of Security Holders Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits

Catalyst Pharmaceuticals Announces Topline Results From Two-Part Phase 1 Clinical Study Of Vamorolone In Healthy Adult Volunteers

Piper Sandler Maintains Overweight on Solaris Energy Infr, Raises Price Target to $82

Piper Sandler analyst Derek Podhaizer maintains Solaris Energy Infr (NYSE:SEI) with a Overweight and raises the price target from $80 to $82.

Solaris Energy Makes Equity Investment In Deployable Energy And Intends To Collaborate On Commercialization Of Deployable Microreactor Technology

Strategic partnership set to advance commercialization of deployable small modular reactor technology for critical energy infrastructureHOUSTON, Aug. 10, 2026 /PRNewswire/ -- Deployable Energy today announced that

Barclays Maintains Overweight on Solaris Energy Infr, Raises Price Target to $90

Barclays analyst David Anderson maintains Solaris Energy Infr (NYSE:SEI) with a Overweight and raises the price target from $86 to $90.